Why drug policy failure is a fiduciary problem too 

Professor Dan Howard SC spent 15 months as commissioner of a NSW Special Commission of Inquiry into the drug ice, produced 109 recommendations, and watched as the government sat on most of them. In conversation with Conexus Financial founder and managing director Colin Tate AM, Howard said six years on nothing has materially changed in drug policy, and that the costs land on everyone, including superannuation funds and their members.

The ‘shadow AI risk’ haunting super funds

Super funds are coming under increasing pressure from APRA and ASIC to demonstrate how they’re using and thinking about AI. For many of them, the AI “shadow risk” in their organisations might be greater than the footprint of their official program.

Why super’s home country bias isn’t a bad thing

Super funds have more than doubled their exposures to global equities in the past 15 years, but it is a misconception that the surge came at the expense of Australian stocks allocation. At the Investment Magazine Fiduciary Investors Symposium, investors examined the changing portfolio role of Australian equities and whether it remains a strong market for active management.

‘A completely different paradigm’: Blackstone on generating returns from the energy transition

The global energy transition is accelerating, driven by rising power demand across the electrification ecosystem. The Investment Magazine Fiduciary Investors Symposium heard how private capital at scale can harness electrification trends to create attractive risk-adjusted returns for investors.

‘It’s crazy’: More gold than bonds in AMP MySuper portfolios while funds rethink defensive plays

The shifting global economic landscape and its impact on currency markets are forcing asset owners to re-think the defensive portion of portfolios as traditional hedging techniques become less effective and new ones emerge. The Fiduciary Investors Symposium heard that for one fund that’s led to gold overtaking government bond allocations.